HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Paul De Bruecker is named senior VP and general manager of Schwarzkopf & Henkel in the U.S. and Canada, overseeing hair care brands got2b, L.A. Looks, Dep and Citre Shine, firm announces Aug. 1. Under his leadership, Henkel expects to accelerate marketing and product development efforts in North America, a targeted growth region, firm adds. Exec, who replaces Thomas Parr, has been with Henkel for more than 15 years, most recently serving as general manager of Schwarzkopf & Henkel in Austria. Henkel's Cosmetics/Toiletries division revenue advanced 4.1% to $843.5 mil. (€1=$1.23) in the second quarter, after adjusting for foreign currency effects, firm says Aug. 3. North American sales increased 18.7% after adjusting for foreign exchange to $828.7 mil., due primarily to acquisitions. Net revenues were up 10% to $3.71 bil. after adjusting for exchange. Earnings grew .5% to $241.7 mil. after minority interests...

You may also be interested in...

Fragrance Creators Association Readies New Consumer Website To Cap ‘Year For The Public’

Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts